Potential new urinary markers in the early detection of bladder cancer

Current Opinion in Urology

Volumn 19, Issue 5, 2009, Pages 488-493

  Shirodkar, Samir P ^a   Lokeshwar, Vinata B ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Bladder cancer; Molecular diagnostics; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; CELL CYCLE PROTEIN; MATRIX METALLOPROTEINASE; MEMBRANE ANTIGEN; NUCLEAR MATRIX PROTEIN; SURVIVIN; TUMOR MARKER;

BLADDER CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENOMICS; HEMATURIA; HUMAN; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; URINE;

EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; GENOMICS; HUMANS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 68949183335     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32832eb3a0     Document Type: Review

References (47)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006; 107:2173-2179.
3. Grossfeld GD, Wolf JS Jr, Litwan MS, et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician 2001; 63:1145-1154.
4. Nieder AM, Lotan Y, Nuss GR, et al. Are patients with hematuria appropriately referred to urology? A multiinstitutional questionnaire based survey. Urol Oncol 2008 (in press).
5. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005; 66:35-63. (Pubitemid 43049608)
6. Yossepowitch O, Herr HW, Donat SM. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol 2007; 177: 1277-1282.
7. Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur Urol 2008; 53:909-916.
8. Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 2006; 24:5528-5535.
9. Messing E. Markers of detection. Urol Oncol 2007; 25:344-347.
10. Shirodkar SP, Lokeshwar VB. Bladder tumor markers: from hematuria to molecular diagnostics - where do we stand? Expert Rev Anticancer Ther 2008; 8:1111-1123.
11. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 2006; 24:326-337.
12. Herman MP, Svatek RS, Lotan Y, et al. Urine-based biomarkers for the early detection and surveillance of nonmuscle invasive bladder cancer. Minerva Urol Nefrol 2008; 60:217-235.
13. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008; 2:212-221.
14. Bennett A. Telomerase and other novel approaches to bladder cancer detection. Clin Lab Sci 2008; 21:185-190.
15. Schiffer E, Mischak H, Theodorescu D, Vlahou A. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World J Urol 2008; 26:67-74.
16. Diamandis EP. How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. Clin Chem 2004; 50:793-795.
17. Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev 2002; 1:683-695.
18. TanakaT, Bai Z, Srinoulprasert Y, et al. Chemokines in tumor progression and metastasis. Cancer Sci 2005; 96:317-322.
19. Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 2006; 66: 3071-3077.
20. Kawanishi H, Matsui Y, Ito M, et al. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res 2008; 14:2579-2587.
21. Otto G, Burdick M, Strieter R, Godaly G. Chemokine response to febrile urinary tract infection. Kidney Int 2005; 68:62-70.
22. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189:300-308.
23. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-21494.
24. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev 2002; 2:161-174.
25. Roy R, Louis G, Loughlin KR, et al. Tumor-specific urinary matrix metallo-proteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res 2008; 14:6610-6617.
26. Smalley DM, Sheman NE, Nelson K, Theodorescu D. Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Pro-teome Res 2008; 7:2088-2096.
27. Vrooman OP, Witjes JA. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol 2009; 16:234-243.
28. Lodde M, Fradet Y. The detection of genetic markers of bladder cancer in urine and serum. Curr Opin Urol 2008; 18:499-503.
29. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365: 488-492. (Pubitemid 40215731)
30. Wang Y, Barbacioru C, Hyland F, et al. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 2006; 7:59.
31. Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J Urol 2007; 25:563-571.
32. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 2008; 18:1-8.
33. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary noninvasive bladder (pTa) tumors. Am J Pathol 2001; 158:1955-1959.
34. Ewart-Toland A, Briassouli P,de Koning JP, etal. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 2003; 34:403-412.
35. Park HS, Park WS, Bondaruk J, et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008; 100:1401-1411.
36. Hanke M, Kausch I, Dahmen G, et al. Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel markerfor bladder cancer. Clin Chem 2007; 53:2070-2077.
37. Rosser CJ, Liu L, Sun Y, et al. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev 2009; 18:444-453.
38. Holyoake A, O'Sullivan P, Pollock R, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res 2008; 14:742-749.
39. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2009. [Epub ahead of print].
40. Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci 2008; 99:646-652.
41. Lam T, Nabi G. Potential of urinary biomarkers in early bladder cancer diagnosis. Expert Rev Anticancer Ther 2007; 7:1105-1115.
42. Kim YK, Kim WJ. Epigenetic markers as promising prognosticatorsfor bladder cancer. Int J Urol 2009; 16:17-22.
43. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-1159.
44. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16:168-174.
45. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-2054.
46. Lin HH, Ke HL, Huang SP, et al. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol 2009 (in press).
47. Yu J, Zhu T, Wang Z, et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007; 13:7296-7304.